Compare Johnson & Johnson (JNJ) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Orion Office REIT Inc — how do they compare? Johnson & Johnson trades at $248.49 (market cap $598.96B), while Orion Office REIT Inc trades at $2.65 (market cap $150.60M). The key difference: Johnson & Johnson is far larger — about 3977.2× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| JNJ | ONL | |
|---|---|---|
Market Cap | $598.96B | $150.60M |
Volume | 6,156,228 | — |
Sector | Health | Real Estate |
52-Week High | $267.24 | $3.04 |
52-Week Low | $164.36 | $1.93 |
Enterprise Value | $631.90B | $634.25M |
Dividend Yield | 2.15% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
ONL trades at $2.65, up 0.76% today, with a bullish technical signal despite bearish moving averages. The company reported Q1 2026 earnings with a net loss of $0.24 per share, missing estimates, while revenue declined to $147.65 million in 2025. A strategic review is underway with Wells Fargo and JPMorgan, focusing on portfolio repositioning and debt management, as highlighted in recent earnings calls (MarketBeat, 2026-05-14).
Outlook remains challenging due to persistent losses and high leverage, but the strategic shift toward dedicated-use assets and resolved refinancing risks offer potential upside. Investors face significant execution and market headwinds, with analyst consensus split evenly between Buy and Hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
